Home/Filings/4/0001193125-26-010361
4//SEC Filing

HASTINGS DAVID C 4

Accession 0001193125-26-010361

CIK 0001563880other

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 4:05 PM ET

Size

5.4 KB

Accession

0001193125-26-010361

Insider Transaction Report

Form 4
Period: 2026-01-08
HASTINGS DAVID C
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-01-08+375,000375,000 total
    Exercise: $11.21Exp: 2036-01-07Common Stock (375,000 underlying)
Footnotes (1)
  • [F1]This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.
Signature
/s/ Christopher Galletta, attorney-in-fact|2026-01-12

Documents

1 file

Issuer

Trevi Therapeutics, Inc.

CIK 0001563880

Entity typeother

Related Parties

1
  • filerCIK 0001237401

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 4:05 PM ET
Size
5.4 KB